Collaborations
Building a Strong Partnership with Precigen
Our exclusive channel collaboration arrangement with Precigen contemplates the use of Precigen’s advanced transgene and cell engineering platforms for the development and production of lantibiotics and LBP.
ECC-Lantibiotics
Our ECC with Precigen grants us access to use their advanced transgene and cell engineering platforms for the development and production of lantibiotics, a class of peptide antibiotics that are naturally produced in Gram-positive bacteria and contain the characteristic polycyclic thioether amino acids lanthionine and methyllanthonine (collectively, the “Lantibiotics Program”).
ECC-Oral Mucositis
Our ECC with Precigen allows us to pursue the development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat and esophagus.